| BUSINESS INFORMATION |
Biotech firms wrap up deals Amgen has finalized its acquisition of Tularik for what a recent Securities & Exchange Commission filing by Amgen said was a purchase price of about $1.5 billion. The Tularik clinical candidates that pass on to Amgen are T67, an anticancer agent that has been in Phase I and II trials; T487, a small molecule targeting inflammatory conditions; T131 for type 2 diabetes; and T71 for obesity treatment |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |